RemeGen's stock price plummeted 5.38% during intraday trading on Monday, reflecting significant selling pressure in the biotech sector.

The decline was primarily driven by escalating regulatory tensions between the US and China. US lawmakers recently proposed incorporating biotechnology into the COINS Act restricted list, aiming to limit American capital flows into Chinese innovative drug companies. This proposal directly cited major cross-border business development transactions as justification. Simultaneously, reports indicate Chinese regulators may impose pre-approval requirements on overseas transactions involving antibody, targeted therapy, small nucleic acid, and cell-gene therapy technologies.

These dual regulatory barriers have undermined the core valuation logic for Chinese biotech companies, where overseas business development expectations serve as the primary valuation anchor. Additionally, institutional selling pressure contributed to the decline, with Oriental Securities recently reducing its RemeGen holdings, while ETF funds tracking the stock recorded significant net outflows over recent weeks.